Oncology

Vertex pharmaceutical’s growth story in biotech with Symdeko’s approval FDA has recently approved Vertex Pharmaceutical’s latest combination treatment, Symdeko, to serve the cystic fibrosis patient population. Symdeko's annual list price has been set at USD 292,000. Symdeko has paired with a fresh corrector, tezacaftor, with the active ingredient in Kalydeco, ivacaftor. Vertex assumes that the combo will get the approval & Orkambi’s uptake will grow gradually. Erytech targeting solid tumors through Red blood cell-encapsulated drug therapy Disappointed from the leukemia data French biotech Erytech is now refocusing on its red blood cell-encapsulated drug therapy to ...